Yang Lili, Pan Zhaojun, Wang Jing, et al. Oral Valganciclovir in the Treatment of Neonatal Congenital Cytomegalovirus Infection: a Case Report. [J]. 27(2):12-14(2021)
DOI:
Yang Lili, Pan Zhaojun, Wang Jing, et al. Oral Valganciclovir in the Treatment of Neonatal Congenital Cytomegalovirus Infection: a Case Report. [J]. 27(2):12-14(2021) DOI: 10.13407/j.cnki.jpp.1672-108X.2021.02.004.
Oral Valganciclovir in the Treatment of Neonatal Congenital Cytomegalovirus Infection: a Case Report
Objective: To probe into the efficacy of oral valganciclovir in the treatment of a case of neonatal congenital cytomegalovirus infection. Methods: A newborn with congenital cytomegalovirus infection was treated with oral administration of 16 mg/kg bid valganciclovir for 6 weeks. Body weight
head circumference
neutrophils
platelets
direct bilirubin
alanine aminotransferase and viral load were monitored; and follow-up was performed on cranial ultrasound
brainstem auditory evoked potential and head magnetic resonance imaging (MRI). Results: At the end of therapy
the newborn was negative for cytomegalovirus in urine and plasma
the hearing and developmental results were improved. Granulocytopenia that occurred during treatment were improved after treatment. Conclusions: Oral valganciclovir is effective in the treatment of congenital cytomegalovirus infection
and further research is needed to determine the optimal dose and course of treatment to achieve better efficacy and safety.